News
-
-
PRESS RELEASE
Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
Aspire Biopharma achieves IRB approval for Phase I clinical trial of fast-acting high-dose aspirin formulation, targeting rapid drug delivery and enhanced bioavailability for suspected acute myocardial infarction treatment -
-
-
-
-
-
PRESS RELEASE
Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
Aspire initiates Phase 1 trial for high-dose aspirin formulation to target acute myocardial infarction. Trial to evaluate safety, pharmacokinetics, pharmacodynamics, with fast track FDA application -
-
PRESS RELEASE
Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin
Aspire announces completion of GMP Clinical Batch for high-dose sublingual aspirin with fast-acting formulation. Company to commence bioavailability study in April 2025 and request 'fast track' FDA approval
